This paper was commissioned for the aids2031 Science and Technology Working Group as part of a series of working papers under the aids2031 initiative. This paper explores issues that could be included in a future research agenda to enhance drug development for HIV/AIDS, including the optimal time to begin antiretroviral therapy, appropriate dosing of antiretrovirals, possible implications of HIV on advanced aging, and an exploration of recent challenges in drug development.
Author(s): Becker S
Corporate author(s): aids2031 Science and Technology Working Group
Publication date: November 2008
179 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
This publication is part of the series aids2031 working papers
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA